Galimedix Therapeutics, Inc.
Christopher Parsons is an accomplished pharmacologist with extensive experience in neuropharmacology and drug development. Currently serving as Chief Pharmacologist and VP of Non-Clinical Development at Galimedix Therapeutics, Inc. since January 2019, Christopher also operated as a Senior Consultant from July 2017 to December 2018. Previously, Christopher held the position of Principal Scientific Expert in Pharmacology at Merz Pharmaceuticals for over 26 years, where responsibilities included leading the In Vitro Pharmacology department. Academic contributions include postdoctoral research at the Max Planck Institute for Psychiatry and Bristol Medical School, with a solid educational foundation featuring a Ph.D. and Privat Dozent in Neuropharmacology. Christopher's technical expertise encompasses a variety of methodologies, particularly in the fields of electrophysiology, molecular biology, and biochemistry.
This person is not in any teams
This person is not in any offices
Galimedix Therapeutics, Inc.
Galimedix Therapeutics is a Phase 2 neuropharmaceutical company developing novel first-in-class drugs with ground-breaking potential to slow or stop the progression of neurodegeneration and to improve function in glaucoma and dry AMD – leading causes of blindness – and also in Alzheimer’s disease.